In a surprising turn within the biotechnology sector, Leap Therapeutics has rebranded as Cypherpunk Technologies, signaling a strategic shift towards cryptocurrency investment. This decision comes as the company attempts to navigate challenging market conditions while focusing on its substantial holdings of digital currency, specifically $50 million worth of Zcash (ZEC).
Leap’s original mission centered around the development of the anti-DKK1 antibody, sirexatamab, targeting various cancers. However, the company faced significant setbacks as it laid off approximately 75% of its workforce in June, a move aimed at conserving cash and maintaining operations. Following these layoffs, Leap communicated its intent to explore strategic alternatives, including potential sales or partnerships for sirexatamab and FL-501, another candidate in preclinical development for a wasting syndrome.
Despite the turbulence, Leap highlighted a positive trend in the response rates during phase 2 studies of sirexatamab in colorectal cancer (CRC), although it cited “current market conditions” as the primary reason for winding down its clinical program. By October, prospects looked more promising with a $58 million private investment from Winklevoss Capital, aimed at initiating a digital asset treasury strategy. This investment is set to allow the biotechnology firm to engage with digital assets while still pursuing therapeutic program developments.
Emphasizing the drug’s potential, CEO Douglas Onsi noted the promising objective response rate of 38% for sirexatamab in combination with Avastin during phase 2 trials. He reaffirmed plans to utilize resources from Winklevoss’ investment for engagement with regulatory authorities regarding the drug’s path to registration in CRC and to enhance the DKK1 biomarker diagnostic test.
The recent announcement of the rebranding to Cypherpunk Technologies underscores a shift in focus towards ZEC, a cryptocurrency that the company has strongly invested in from the proceeds of its latest private placement. Alongside the rebranding, significant leadership changes were made; Khing Oei will replace Christopher Mirabelli, Ph.D., as chair of the board, while Will McEvoy of Winklevoss Capital will assume the newly created position of chief investment officer.
Onsi expressed excitement over the new direction, highlighting the critical nature of participant control and privacy in financial transactions transitioning towards blockchain technology. He characterized the rebrand and leadership changes as transformative steps in expanding the company’s mission and entering a novel phase of growth.
Leap is not alone in this strategic pivot. Just last September, MEI Pharma rebranded as Lite Strategy to reflect its investment in cryptocurrency, namely Litecoin. Other biotech firms like Conduit Pharmaceuticals, Propanc Biopharma, and MAIA Biotechnology have also begun considering the accumulation of various digital currencies in response to evolving market landscapes.
This trend underscores an emerging pattern of drug developers exploring alternative revenue streams and investment strategies in the volatile world of cryptocurrencies, as the biotech industry faces ongoing pressures.
